Nisa Investment Advisors LLC Trims Stake in Janux Therapeutics, Inc. (NASDAQ:JANX)

Nisa Investment Advisors LLC lessened its holdings in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) by 41.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,867 shares of the company’s stock after selling 8,476 shares during the period. Nisa Investment Advisors LLC’s holdings in Janux Therapeutics were worth $635,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of JANX. Dimensional Fund Advisors LP increased its stake in Janux Therapeutics by 54.0% in the second quarter. Dimensional Fund Advisors LP now owns 24,019 shares of the company’s stock worth $1,005,000 after purchasing an additional 8,422 shares during the period. Amalgamated Bank boosted its position in Janux Therapeutics by 61.1% in the 2nd quarter. Amalgamated Bank now owns 970 shares of the company’s stock valued at $41,000 after buying an additional 368 shares during the period. AQR Capital Management LLC bought a new position in Janux Therapeutics in the 2nd quarter worth about $215,000. The Manufacturers Life Insurance Company increased its position in shares of Janux Therapeutics by 234.7% during the second quarter. The Manufacturers Life Insurance Company now owns 24,048 shares of the company’s stock worth $1,007,000 after acquiring an additional 16,864 shares during the period. Finally, Point72 Asset Management L.P. purchased a new stake in shares of Janux Therapeutics in the second quarter valued at approximately $5,715,000. Institutional investors own 75.39% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on JANX. Scotiabank lifted their target price on Janux Therapeutics from $42.00 to $62.00 and gave the company a “sector perform” rating in a research report on Wednesday, December 4th. Lifesci Capital raised shares of Janux Therapeutics to a “strong-buy” rating in a research note on Friday, December 27th. William Blair reissued an “outperform” rating on shares of Janux Therapeutics in a research report on Friday, January 10th. Leerink Partnrs upgraded shares of Janux Therapeutics to a “strong-buy” rating in a research note on Friday, November 22nd. Finally, Stifel Nicolaus boosted their price objective on shares of Janux Therapeutics from $70.00 to $115.00 and gave the stock a “buy” rating in a research note on Tuesday, December 3rd. One research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Janux Therapeutics presently has an average rating of “Buy” and a consensus price target of $89.90.

Insider Buying and Selling at Janux Therapeutics

In other news, insider Andrew Hollman Meyer sold 13,334 shares of Janux Therapeutics stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $54.88, for a total value of $731,769.92. Following the completion of the sale, the insider now directly owns 82,139 shares of the company’s stock, valued at approximately $4,507,788.32. The trade was a 13.97 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO David Alan Campbell sold 5,000 shares of the stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $60.00, for a total transaction of $300,000.00. Following the sale, the chief executive officer now directly owns 293,054 shares in the company, valued at $17,583,240. This represents a 1.68 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 83,334 shares of company stock worth $4,731,520 over the last quarter. 29.40% of the stock is currently owned by company insiders.

Janux Therapeutics Price Performance

NASDAQ:JANX opened at $41.88 on Wednesday. Janux Therapeutics, Inc. has a 1-year low of $7.79 and a 1-year high of $71.71. The firm has a market capitalization of $2.20 billion, a P/E ratio of -35.79 and a beta of 3.23. The company’s fifty day moving average price is $51.90 and its 200-day moving average price is $48.47.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.18). Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. The business had revenue of $0.44 million for the quarter, compared to analyst estimates of $1.50 million. The business’s revenue was down 82.6% compared to the same quarter last year. Equities analysts anticipate that Janux Therapeutics, Inc. will post -1.38 EPS for the current fiscal year.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.